Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study by Hoff, M et al.
Adalimumab therapy reduces hand bone loss in early
rheumatoid arthritis: explorative analyses from the
PREMIER study
M Hoff,
1,2 T K Kvien,
3,4 JK a ¨lvesten,
5 A Elden,
6 G Haugeberg
2,7
c An additional table is
published online only at http://
ard.bmj.com/content/vol68/
issue7
1Department of Rheumatology,
St Olav’s Hospital, Trondheim,
Norway;
2Norwegian University
of Science and Technology,
Trondheim, Norway;
3Department of Rheumatology,
Diakonhjemmet Hospital, Oslo,
Norway;
4Faculty of Medicine,
University of Oslo, Oslo, Norway;
5Sectra, Linko ¨ping, Sweden;
6Abbott Laboratories, Oslo,
Norway;
7Department of
Rheumatology, Sørlandet
Hospital, Kristiansand S, Norway
Correspondence to:
Dr M Hoff, University Hospital of
Trondheim, Norwegian
University of Science and
Technology, MTFS, Department
of Neuroscience, Division of
Rheumatology, NO-7489
Trondheim, Norway;
mari.hoff@ntnu.no
Accepted 6 September 2008
Published Online First
16 September 2008
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
ard.bmj.com/info/unlocked.dtl
ABSTRACT
Objective: The effect of adalimumab on hand osteo-
porosis was examined and related to radiographic joint
damage in the three treatment arms of the PREMIER
study: adalimumab plus methotrexate, adalimumab and
methotrexate monotherapy. Predictors of hand bone loss
were also searched for.
Methods: 768 patients (537 fulfilled 2 years) with
rheumatoid arthritis (RA) for less than 3 years, never
treated with methotrexate, were included. Hand bone loss
was assessed by digital x ray radiogrammetry (DXR) on
the same hand radiographs scored with modified Sharp
score at baseline, 26, 52 and 104 weeks. For DXR,
metacarpal cortical index (MCI) was the primary bone
measure.
Results: At all time points the rate of percentage DXR–
MCI loss was lowest in the combination group (21.15;
22.16; 23.03) and greatest in the methotrexate
monotherapy group (21.42; 22.87; 24.62), with figures
in between for the adalimumab monotherapy group
(21.33; 22.45; 24.03). Significant differences between
the combination group and the methotrexate group were
seen at 52 (p=0.009) and 104 weeks (p,0.001). The
order of hand bone loss across the three treatment arms
was similar to the order of radiographic progression. Older
age, elevated C-reactive protein and non-use of adali-
mumab were predictors of hand bone loss.
Conclusion: This study supports a similar pathogenic
mechanism for hand bone loss and erosions in RA. The
combination of adalimumab and methotrexate seems to
arrest hand bone loss less effectively than radiographic
joint damage. Quantitative measures of osteoporosis may
thus be a more sensitive tool for assessment of
inflammatory bone involvement in RA.
In rheumatoid arthritis (RA), bone damage on
radiographs presents not only as erosions but also
as periarticular osteoporosis.
1 Hand bone loss in
early RA has been shown to occur more rapidly
than bone loss at the hip and spine
2–4 and also
predicts radiographic joint damage.
5
Inflammatory activation of the osteoclast is
involved in both features. Studies support that
cytokines, eg, tumour necrosis factor (TNF) alpha,
macrophage colony-stimulating factor and receptor
activator of nuclear factor kappa ligand (RANKL),
activate the osteoclast that causes osteoporosis
(localised and generalised) and erosions.
6–8
Anti-TNF therapy has been shown to reduce the
progression of radiographic joint damage signifi-
cantly in RA patients.
9–11 A few studies have also
suggested that anti-TNF therapy may prevent
general bone loss.
12–14
Quantitative hand bone measures have been
recommended for their sensitivity to assess inflam-
matory bone involvement in early RA.
15 However,
only a few studies have examined the effect of anti-
inflammatory treatment (including anti-TNF ther-
apy) on hand bone loss in RA.
41 41 61 7Furthermore,
only one randomised controlled trial has been
conducted in which the anti-inflammatory effects
of prednisolone (7.5 mg daily) compared with
placebo were shown to reduce significantly not
only the rate of radiographic joint damage, but also
the rate of hand bone loss.
17
The primary objective of this analysis was to
examine cortical hand bone loss in the three arms
of the PREMIER study: adalimumab plus metho-
trexate versus adalimumab monotherapy versus
methotrexate monotherapy and to evaluate asso-
ciations between hand bone loss and radiographic
progression. Our second objective was to identify
potential predictors of hand bone loss.
METHODS
Study sample and design
The radiographic and clinical data from this 2-year,
multicentre, double-blind, randomised controlled
study (PREMIER) have previously been described
in detail.
11 In short, the efficacy and safety of
adalimumab plus methotrexate was compared
with adalimumab monotherapy and with metho-
trexate monotherapy in 799 adult patients with
early (,3 years, mean disease duration
9.1 months), aggressive RA (inclusion criteria: >8
swollen joints; erythrocyte sedimentation rate >28
or C-reactive protein (CRP) >1.5 mg/dl; erosions
or rheumatoid factor positive), who previously had
not been treated with methotrexate, cyclopho-
sphamide, cyclosporine, azathioprine or more than
two other disease-modifying antirheumatic drugs
(DMARD) (table 1).
11 The combination group
received adalimumab 40 mg subcutaneously every
other week plus weekly methotrexate by mouth
(rapidly increased to 20 mg/week), and the mono-
therapy groups received either adalimumab 40 mg
subcutaneously every other week plus placebo or
weekly methotrexate by mouth plus placebo.
Radiographs from hands and feet were scored
according to the modified Sharp score (range 0–
398).
11
From this study, we present hand bone loss data
at 26, 52 and 104 weeks of follow-up. To maintain
the original study design of a blinded randomised
controlled trial, the treatment code was kept secret
for one of the authors who analysed the data
(MH).
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Digital x ray radiogrammetry (DXR; Sectra, Linko ¨ping, Sweden)
was used to measure hand bone mineral density (BMD) and the
metacarpal cortical index (MCI) on the same digitised hand x
rays used for the assessment of radiographic joint damage. DXR
is a computer version of the traditional radiogrammetry
technique
18 and the method has previously been described in
detail.
19–21 On hand radiographs, the computer automatically
recognises regions of interest around the narrowest part of the
second, third and fourth metacarpal bone and measures cortical
thickness, bone width and porosity 118 times per centimetre.
DXR–BMD is defined as: c 6VPAcomb 6(1 2 p), where c is a
density constant, VPA is volume per area and p is porosity.
DXR–MCI is defined as the combined cortical thickness divided
by the bone width and is a relative bone measure independent
of bone size and bone length.
21 22 In the literature short-time in-
vivo precision (CV%) has been reported to range from 0.28% to
0.59% for DXR–BMD and from 0.31% to 0.64% for DXR–
MCI.
19 21 23
DXR–BMD was intended to be the main outcome measure in
this study. However, many radiographs could not be analysed
for BMD because of unknown image resolution. The equation
for DXR–BMD is based on volume per area and requires a
known resolution, because a distance in a digitised radiograph
cannot be measured when the resolution is unknown.
Therefore, DXR–MCI, which is a relative measure less
dependent on image resolution, was used as the primary
outcome measure. The correlation between DXR–BMD and
DXR–MCI has been shown to be substantial (r . 0.90), both
cross-sectionally
24 and longitudinally.
25
For comparison, we also present results for DXR–BMD. All
images with unknown resolution were analysed by assuming
254 dpi (the scanning resolution for the radiographs before
scoring). Several of the radiographs were, however, clearly of a
resolution other than 254 dpi, most likely because these
radiographs had been printed in non-true size before scanning.
We analysed all available images for DXR–BMD at baseline, as
well as 26, 52 and 104 weeks and calculated DXR width. Based
on analyses from studies with a controlled resolution,
25 a
deviation from baseline width greater than 2% was likely to
indicate an incorrect value. By using this 2% value as a cut-off,
23% of the radiographs were excluded from further DXR–BMD
analyses. The flow chart in fig 1 illustrates the patients who
were included in the DXR–MCI and DXR–BMD analyses.
To avoid bias regarding dominant and non-dominant hand
and to achieve better precision, we employed mean value
measurements from both hands.
15 If the radiograph from one
hand could not be analysed, we used the radiograph from the
available hand for all analyses at all time points.
The radiographs were acquired by a single emulsion
mammography film; film focus distance 100 cm; tube voltage
50–55 kV according to the radiographic equipment and the
exposure dose was 8 mAs.
Statistical analysis
As the data were skewed, non-parametric analyses were
conducted. No imputations were performed. Baseline values
were compared between treatment groups with the Kruskall–
Wallis method for continuous variables and the x
2 method for
categorical variables. Comparisons of changes in DXR were
conducted using methodologies employed in the original
PREMIER study.
11 Two groups were compared in a hierarchical
order with the Mann–Whitney U test, ie, two-sided comparison
of the combination group versus methotrexate, followed by
two-sided comparisons between the adalimumab monotherapy
and methotrexate monotherapy treatment arms and finally
two-sided comparisons between the adalimumab monotherapy
and the combination group. Each pair-wise comparison was
completed only if the previous comparison was statistically
significant. Bone loss over time was expressed as a negative
value.
A linear regression model was developed to search for
predictors of hand BMD loss at 26, 52 and 104 weeks.
Table 1 Baseline characteristics for early RA patients in PREMIER*
Adalimumab +
methotrexate
(N = 261)
Adalimumab
monotherapy
(N = 261)
Methotrexate
monotherapy
(N = 246)
Demographic characteristics
Age, years 52.2 (13.8) 51.9 (13.7) 51.9 (13.3)
Female, no (%) 187 (71.6) 205 (78.5) 181 (73.6)
Clinical characteristics
Disease duration, years 0.7 (0.8) 0.7 (0.8) 0.8 (0.9)
Previously taken DMARD, no (%) 84 (32.2) 87 (33.3) 78 (31.7)
Previously taken corticosteroids, no (%) 92 (35.2) 94 (36.0) 85 (34.6)
Tender joint count, 0–66 31.1 (14.1) 31.7 (13.5) 32.2 (14.3)
Swollen joint count, 0–66 21.2 (11.1) 21.7 (10.2) 21.6 (11.3)
C-reactive protein, mg/l 39.5 (42.4) 40.7 (38.6) 40.6 (41.2)
HAQ, 0–3 1.5 (0.6) 1.6 (0.6){ 1.5 (0.7)
DAS28 6.3 (0.9) 6.4 (0.9) 6.3 (0.9)
Image analysis
Modified TSS
Mean 18.1 (20.3) 18.4 (18.2) 21.5 (21.8)
Median (25–75th percentile) 12.8 (6.0–24.0) 13.5 (5.1–25.5) 15.5 (7.5–28.5)
DXR–MCI 0.45 (0.09) 0.45 (0.09) 0.46 (0.08)
DXR–BMD, g/cm
2 0.57 (0.08) 0.57 (0.08) 0.58 (0.08)
*Except where indicated results are given in mean (standard deviation) for continuous variables and numbers and percentages for
categorical variables. {Significantly higher values in the adalimumab group compared with both the methotrexate and the
combination group. BMD, bone mineral density; DAS28, 28-joint disease activity score; DMARD, disease-modifying antirheumatic
drugs; DXR, digital x ray radiogrammetry; HAQ, health assessment questionnaire; MCI, metacarpal cortical index; RA, rheumatoid
arthritis; TSS, total Sharp score.
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correlate changes in DXR–MCI with the following baseline
variables: disease duration; disease activity measured by 28-joint
disease activity score (DAS28);
26 CRP; disability index of health
assessment questionnaire (HAQ) scores;
27 previous use of
DMARD and cortisone; radiographic joint damage; randomised
treatment arm and absolute DXR–MCI value. The variables
with a p value less than 0.15 were included in the multivariate
model, which was also adjusted for age and gender. Treatment
arm was coded as a dummy variable (methotrexate as 0,
adalimumab as 1 and combination group as 2).
The PREMIER study was approved by a central institutional
review board and independent ethics committees at each
participating site.
11
RESULTS
Baseline DXR–MCI values were available for 768 of the 799
patients enrolled in the PREMIER study and DXR–MCI values
were missing for two of 539 patients who completed the study
(fig 1). The corresponding numbers for available DXR–BMD
data (based on the cut-off values for image resolution described
in the Methods section) were 765 and 369, respectively (fig 1).
Demographics and baseline clinical characteristics for the whole
group were comparable between the three treatment arms
(table 1).
The only statistically significant difference between treat-
ment arms was a slightly greater mean HAQ score for the
adalimumab monotherapy group. Before enrollment, corticos-
teroids had been used in 35% of the patients (mean daily dosage
of prednisolone was 6.6 mg) and 32% had been treated with
traditional DMARD other than methotrexate. The baseline
radiographic damage scores were similar across treatment
groups, with a median (mean) Sharp score of 14.0 (19.3)
(table 1).
Median percentage DXR–MCI changes for all patients were
21.29, 22.45 and 23.72 at 26, 52 and 104 weeks.
Corresponding values for DXR–BMD were 21.07%, 21.72%
and 22.63%. Changes from baseline in DXR–MCI and DXR–
BMD were significant for all subgroups at all time points during
follow-up (p,0.001 for all). The use of corticosteroids or
DMARD did not affect hand bone loss (data not shown).
Correlation coefficients (r) between the DXR–MCI and the
DXR–BMD changes were 0.88, 0.93 and 0.94 at 26, 52 and
104 weeks (p,0.001 for all).
DXR–MCI changes between treatment arms
At 26, 52 and 104 weeks follow-up median percentage DXR–
MCI changes were 21.15, 22.16 and 23.03 for the adalimumab
plus methotrexate combination group, 21.33, 22.45 and 24.03
for the adalimumab monotherapy group and 21.42, 22.87 and
24.62 for the methotrexate monotherapy group (fig 2).
The rate of DXR–MCI loss was significantly greater for the
methotrexate group compared with the combination group at
Figure 1 Flow chart of the examined patients with early rheumatoid
arthritis in the present analysis. Numbers of missing x rays compared
with the original PREMIER study are provided in parentheses. BMD, bone
mineral density; DXR, digital x ray radiogrammetry; MCI, metacarpal
cortical index; MTX, methotrexate.
Figure 2 Changes in DXR–MCI (percentage) and modified Sharp score
(units) over time in the three treatment groups of PREMIER (A, median
values; B, mean values). DXR, digital x ray radiogrammetry; MCI,
metacarpal cortical index; Mod Sharp, modified total Sharp score; MTX,
methotrexate.
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trend was also observed at 26 weeks (p=0.19). DXR–MCI
reduction in the adalimumab monotherapy group was numeri-
cally lower than in the methotrexate group at 104 weeks
(p=0.10).
DXR–BMD changes between treatment arms
The median DXR–BMD percentage changes at 26, 52 and
104 weeks were, respectively, 21.06, 21.63 and 22.49 in the
combination group, 20.96, 21.97 and 22.40 for the adalimu-
mab group and 21.20, 21.86 and 23.58 for the methotrexate
group. The median DXR–BMD loss in the adalimumab group
was numerically slightly less than in the combination group
both at 26 and 104 weeks. However, the mean loss in the
adalimumab group was greater at all time points (see
supplementary table available online only). A significant
difference between the DXR–BMD change in the methotrexate
group and the combination group at 104 weeks (p=0.049) was
observed and a trend at 52 weeks (p=0.10). A trend towards a
difference between the methotrexate and adalimumab groups
was observed at 104 weeks (p=0.16).
Analyses on DXR–cortical thickness (DXR–CT) and DXR–
bone width (DXR–W) were also performed on the same
subgroups that were analysed for DXR–BMD. DXR–CT
showed the same pattern of bone loss as DXR–BMD and
DXR–MCI. DXR–W was stable at all time points and was not
influenced by treatment (see supplementary table available
online only).
DXR–MCI and radiographic damage
The median (mean) radiographic changes in modified Sharp
score at 26, 52 and 104 weeks, respectively, were 0 (0.5), 0 (0.9)
and 0 (1.0) for the combination group, 0.5 (2.1), 0.5 (3.3) and 1.0
(4.8) for the adalimumab monotherapy group and1.0 (3.4), 2.0
(5.1) and 2.0 (6.4) for the methotrexate monotherapy group
(fig 2). The discrepancy in the results of this analysis compared
with findings of the original PREMIER study is probably a result
of the slight differences in the number of study participants
(fig 1) and the fact that no imputations were conducted in the
present study. The correlations (r) between DXR–MCI change
and change in Sharp score at 26, 52 and 104 weeks were
r=20.12 (p=0.001), r = 20.23 (p,0.001) and r = 20.32
(p,0.001). Comparable r values for correlations between DXR–
BMD and Sharp score changes were 20.15, 20.23 and 20.33,
respectively (p,0.001 for all).
Multivariate model
At all time points the variables included in the final multivariate
model were baseline values of disease duration, DAS28 score,
CRP, DXR–MCI, HAQ, radiographic damage and treatment
group (dummy variable), together with age and gender.
At 52 and 104 weeks, older age, greater CRP and non-use of
adalimumab turned out to be independent predictors for
cortical hand bone loss. At 26 weeks, female gender and greater
CRP were predictors of cortical hand bone loss. The model for
104 weeks is depicted in table 2.
DISCUSSION
The key finding of this analysis was that anti-TNF therapy with
adalimumab in combination with methotrexate provided better
bone protection than either adalimumab or methotrexate
monotherapies in patients with early, aggressive RA. The order
of hand bone loss across the three treatment arms was the same
as has been observed for overall radiographic damage in the
PREMIER study (fig 2). Furthermore, the results from the
multivariate model highlight the importance of inflammation
(assessed with CRP) as the driving force for bone damage in
active RA and the importance of TNF involvement in this
process.
The present analysis adds evidence to the hypothesis that
both erosions and osteoporosis are a result of the same
pathophysiological mechanism, which includes activation of
the osteoclast cell. This hypothesis is based on findings from
both animal
62 8and human
7 studies.
Table 2 Predictors for percentage DXR–MCI loss at 104 weeks follow-
up in 515 RA patients explored by a multivariate linear regression model
DXR–MCI percentage change at 104 weeks
Beta p Value
Age, years 20.25 ,0.001
Female gender 20.04 0.36
Disease duration, years 0.06 0.11
C-reactive protein, mg/l 20.23 ,0.001
DAS28 20.09 0.07
Treatment group* 0.16 ,0.001
R
2, adjusted 0.19
*Treatment groups coded as a dummy variable: 0, methotrexate; 1, adalimumab; 2,
adalimumab plus methotrexate. MCI baseline, Sharp score baseline and HAQ did not
influence the model. DAS28, 28-joint disease activity score; DXR, digital x ray
radiogrammetry; HAQ, health assessment questionnaire; MCI, metacarpal cortical
index; RA, rheumatoid arthritis.
Figure 3 Cumulative probability plot: changes in DXR–MCI and
radiographic scores at 104 weeks in PREMIER. DXR, digital x ray
radiogrammetry; MCI, metacarpal cortical index; mod Sharp score,
modified total Sharp score; MTX, methotrexate.
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important to avoid bone damage in RA. Anti-TNF therapy has
in several clinical trials been shown to reduce the progression of
joint erosion.
9–11 Furthermore, there is also evidence that anti-
TNF therapy reduces osteoporosis at the hip and spine.
4 12–14
The ability of anti-inflammatory treatment to reduce hand
bone loss in RA has been demonstrated in a double-blind study
comparing oral prednisolone 7.5 mg/day for 2 years with
placebo. The prednisolone group had less hand BMD loss at 1
and 2 years, suggesting that the potent anti-inflammatory
effect of prednisolone exceeded its negative effect on bone.
17
With respect to the effects of anti-TNF therapy on hand bone
loss in RA, only a few studies have been conducted. RA patients
treated with anti-TNF therapy have been shown to have a
lower rate of bone loss at the spine and hip than at the hand.
41 4
In a 2-year longitudinal treatment strategy study (the BeST
study), RA patients treated with anti-TNF therapy or high-dose
prednisolone were shown to have a lower rate of bone loss at
the hand than patients treated with conventional DMARD.
4
Furthermore, in a study employing quantitative ultrasound, the
use of anti-TNF therapy had a positive effect on periarticular
bone.
16 The beneficial effect of anti-TNF treatment on
inflammatory-related hand bone loss in RA is supported by
our observations.
Methotrexate has been reported to have negative effects on
bone and the term ‘‘methotrexate osteopathy’’ has been used to
describe a clinical syndrome characterised by stress fractures,
diffuse bone pain and osteoporosis in children treated for
malignancies.
29 In animal studies high-dose methotrexate has
been shown to induce apoptosis and suppress proliferation of
the growth plate chondrocytes as well as proliferation of the
osteoblasts and preosteoblasts.
30 However, low-dose methotrex-
ate (5–20 mg/week) both in cross-sectional
31 32 and longitudi-
nal
33 studies has not shown any negative effect of methotrexate
on bone.
Despite the fact that bone loss was considerably lower in the
combination group than in the methotrexate group, these
patients were still losing hand bone. This loss may have been a
result of the substantial disease activity in the PREMIER RA
patients and their poor prognosis in terms of bone damage
(rheumatoid factor-positive and erosive disease).
34
The positive effects of anti-TNF therapy seemed to be more
pronounced for radiographic joint damage than for hand bone
mass (fig 2). One explanation for this may be that conventional
radiographs are not sensitive enough to detect bone damage.
Both ultrasound and magnetic resonance imaging (MRI) have
been demonstrated to be more sensitive than radiographs in
detecting erosions.
35 Furthermore, MRI can detect erosions years
before they become visible on radiographs
36 and MRI synovitis
has been detected in RA patients in both clinical and radio-
graphic remission.
37 Although MRI and ultrasound are sensitive
to detect erosions, there are still some limitations for clinical use
due to availability and the lack of validated scoring systems.
Hand bone loss assessed by dual x ray absorptiometry has also
been shown to be a more sensitive marker for bone damage than
conventional radiographs.
15 Therefore, the combination of ever-
present inflammation in patients with greater disease activity,
as well as the ability of DXR to detect small changes in bone
mass, may explain the ongoing loss of hand bone. It is also
important to note the influence of normal age-related bone loss
that takes place in healthy adults, especially postmenopausal
women. Normal bone loss for DXR–MCI has only been
examined in cross-sectional studies reporting an annual rate of
bone loss between 0.7% and 0.9%.
21 38 39
When this analysis was planned, we intended to analyse
radiographs primarily for DXR–BMD, but for reasons described
in the Methods section, there were difficulties in analysing a
large percentage of the radiographs for DXR–BMD. By using the
relative DXR–MCI measure instead of the absolute measure of
BMD, we lost the opportunity to correct for porosity.
Furthermore, DXR–BMD, as opposed to DXR–MCI, is cali-
brated for blurring and particular qualities of the different
radiographic measurement equipment. However, DXR has
improved the precision of MCI
22 and there is a strong correlation
between DXR–BMD and DXR–MCI (r . 0.9).
24 25 DXR–MCI
and DXR–BMD have also been found to be greatly correlated
with dual x ray absorptiometry–BMD.
25 On the basis of these
facts, we believe DXR–MCI to be a valid surrogate measure of
hand bone mass.
Another limitation was our inability to retrieve information
on the use of bisphosphonates. This may be of importance as
treatment with bisphosphonates increases bone density. For the
potent bisphosphonate, zoledronic acid, the suppression of
osteoclast activity has even been shown to reduce the
progression of erosions both in animal
40 and human
7 studies.
Anti-TNF therapy inhibits the osteoclast by suppressing
inflammation and decreases the RANK/RANKL pathway, while
the aminobisphosphonate zoledronic acid acts directly on
osteoclasts. However, we believe that the study design of a
double-blind, randomised controlled trial has minimised the
effect of this potential bias. In addition, zoledronic acid was not
on the market for osteoporosis treatment when the PREMIER
study was conducted. Furthermore, in an observational study
the positive effect of infliximab on bone was found to be
independent of bisphosphonate use.
12
In conclusion, our analysis of data from PREMIER provides
evidence that potent anti-TNF therapy not only reduces the risk
of developing erosions, but also reduces the rate of inflamma-
tory-related hand bone loss in RA. This study also suggests that
the bone damage disease process is still present in RA patients
treated with TNF antagonists, even if radiographic joint damage
on radiographs is apparently arrested. Based on the findings
from the present and previous studies, quantitative measures of
hand bone loss in RA patients can be recommended as outcomes
for future clinical trials to detect ongoing bone damage.
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